Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background. The clinical course of COVID-19 infection can be significantly affected by severe immunosuppression, viral load, concomitant diseases and conditions not related to HIV, the absence of antiretroviral therapy. It is potentially important to assess the state of post-ovoid immunity for the provision of medical care to HIV-infected patients with COVID-19. Aim: to assess the impact of HIV infection on the clinical course of a new coronavirus infection, the severity of the disease and its outcomes, and immune response. Materials and methods. Medical records of 35,328 patients who underwent COVID-19 in 2020 were analyzed, including 46 cases of SARS-CoV-2 infection in HIV-infected individuals. To determine specific antibodies to SARS-CoV-2, 281 blood samples were examined by ELISA. The clinical course of COVID-19 in HIV-infected patients, as well as the production of IgG to SARS-CoV-2, depending on the level of CD4 and viral load, were assessed. Results. In 76% of co-infected patients, there were signs of progression of HIV infection, opportunistic infections and concomitant diseases. 52.2% of the analyzed group were users of psychoactive substances. Among patients co-infected with HIV and COVID-19, men predominated in the age groups over 30 years old, while among the HIV-negative population, women in the age groups over 18 years old predominated. The proportion of severe forms of COVID-19 in HIV-infected people (47.8%) exceeds that in the group of patients without immunodeficiency (12.3%). The mortality rate from COVID-19 among HIV-infected people was more than 7 times higher than that of the HIV-negative population of the region (t=1.81; p=0.01). Among the examined 72 HIV-infected patients, IgG antibodies to SARS-CoV-2 were detected in 20 patients, of which 4 (28.5%) with confirmed HIV/SARS-CoV-2 co-infection and 16 people (27.5%) without medical confirmation. HIV-infected patients with severe immunodeficiency did not develop a humoral immune response to COVID-19 infection, and in 25% the immune response lasted less than 3 months. Conclusions. HIV-infected patients are at greater risk of developing a severe course of coronavirus infection. The presence of deep immunodeficiency and high viral load in patients without antiretroviral therapy significantly reduces tension and shortens the development and duration of post-COVID immunity.
Background. The clinical course of COVID-19 infection can be significantly affected by severe immunosuppression, viral load, concomitant diseases and conditions not related to HIV, the absence of antiretroviral therapy. It is potentially important to assess the state of post-ovoid immunity for the provision of medical care to HIV-infected patients with COVID-19. Aim: to assess the impact of HIV infection on the clinical course of a new coronavirus infection, the severity of the disease and its outcomes, and immune response. Materials and methods. Medical records of 35,328 patients who underwent COVID-19 in 2020 were analyzed, including 46 cases of SARS-CoV-2 infection in HIV-infected individuals. To determine specific antibodies to SARS-CoV-2, 281 blood samples were examined by ELISA. The clinical course of COVID-19 in HIV-infected patients, as well as the production of IgG to SARS-CoV-2, depending on the level of CD4 and viral load, were assessed. Results. In 76% of co-infected patients, there were signs of progression of HIV infection, opportunistic infections and concomitant diseases. 52.2% of the analyzed group were users of psychoactive substances. Among patients co-infected with HIV and COVID-19, men predominated in the age groups over 30 years old, while among the HIV-negative population, women in the age groups over 18 years old predominated. The proportion of severe forms of COVID-19 in HIV-infected people (47.8%) exceeds that in the group of patients without immunodeficiency (12.3%). The mortality rate from COVID-19 among HIV-infected people was more than 7 times higher than that of the HIV-negative population of the region (t=1.81; p=0.01). Among the examined 72 HIV-infected patients, IgG antibodies to SARS-CoV-2 were detected in 20 patients, of which 4 (28.5%) with confirmed HIV/SARS-CoV-2 co-infection and 16 people (27.5%) without medical confirmation. HIV-infected patients with severe immunodeficiency did not develop a humoral immune response to COVID-19 infection, and in 25% the immune response lasted less than 3 months. Conclusions. HIV-infected patients are at greater risk of developing a severe course of coronavirus infection. The presence of deep immunodeficiency and high viral load in patients without antiretroviral therapy significantly reduces tension and shortens the development and duration of post-COVID immunity.
Relevance. Currently, there is a significant increase in the combination of infectious and non-infectious pathology. as well as increasing the attention of researchers to this problem. The purpose. of this article is to review scientific data on the combination of the new coronavirus infection COVID-19 with infectious and non-infectious pathology and to assess the phenomenon of complex comorbidity in relation to this new infection. Results. It was found that patients 60 years and older - all have complex comorbidity, which increases the risk of death by more than 7 times, and the presence of two or more comorbid diseases in patients compared with patients who had no more than one disease, the risk of death increased by 9 times. Conclusion. A high potential of combination with COVID-19 is shown, primarily with tuberculosis, HIV infection, hepatitis B and C, as well as with a large group of opportunistic infections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.